Skip to Main Content

Paper Details

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.
Drugs Today (Barc)
2
2023
Author NameAffiliation
Antonio Jimenoand Developmental Therapeutics Program University of Colorado Cancer Center
  • 1 - 1

Datasets

Release 1.2